hVIVO plc (LON:HVO – Get Free Report) shares fell 6.8% on Thursday . The stock traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares were traded during trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.26).
hVIVO Price Performance
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock has a market capitalization of £129.95 million, a price-to-earnings ratio of 636.67 and a beta of 0.97. The stock’s 50 day simple moving average is GBX 23.58 and its 200-day simple moving average is GBX 26.77.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
- Five stocks we like better than hVIVO
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Legacy Tech Companies Reemerging as AI Leaders
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Differences Between Momentum Investing and Long Term Investing
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
